About Aldo-keto reductase family 1 member A1
Aldo-keto reductase family 1 member A1 (AKR1A1) is a protein
from Homo sapiens identified by UniProt accession
P14550, 325 residues long.
MolForge cross-references it against 0 known binders and
294 disease associations.
Target properties
| Protein name | Aldo-keto reductase family 1 member A1 |
| UniProt accession | P14550 |
| Gene | AKR1A1 |
| Organism | Homo sapiens |
| Length | 325 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (294)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.42
- glioblastoma multiforme · score 0.16
- glomerular filtration rate · score 0.15
- reticulocyte count · score 0.14
- pulse pressure measurement · score 0.14
- FEV/FVC ratio · score 0.12
- reticulocyte measurement · score 0.11
- serum metabolite measurement · score 0.11
- blood protein measurement · score 0.09
- protein measurement · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P14550-F1 | alphafold | PREDICTED | 96.86 | — |
Amino-acid sequence (325 residues)
MAASCVLLHT GQKMPLIGLG TWKSEPGQVK AAVKYALSVG YRHIDCAAIY GNEPEIGEAL KEDVGPGKAV PREELFVTSK LWNTKHHPED VEPALRKTLA DLQLEYLDLY LMHWPYAFER GDNPFPKNAD GTICYDSTHY KETWKALEAL VAKGLVQALG LSNFNSRQID DILSVASVRP AVLQVECHPY LAQNELIAHC QARGLEVTAY SPLGSSDRAW RDPDEPVLLE EPVVLALAEK YGRSPAQILL RWQVQRKVIC IPKSITPSRI LQNIKVFDFT FSPEEMKQLN ALNKNWRYIV PMLTVDGKRV PRDAGHPLYP FNDPY
Explore Aldo-keto reductase family 1 member A1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets